Cure8 news brief
This project explores whether common environmental chemicals (PFAS) might change biological processes years before IBD appears, which could help explain some cases of Crohn’s disease and ulcerative colitis and point toward early-risk markers or prevention strategies.
Researchers studying environmental drivers of IBD, clinicians interested in IBD risk and prevention, and patients or advocates curious about environmental contributors to IBD risk.
NIH awarded a five-year R01 grant to Mount Sinai investigators to study whether PFAS (per- and polyfluoroalkyl substances) exposures contribute to the development of IBD years before diagnosis.
The project will measure many PFAS chemicals in archived blood samples from the PREDICTS military cohort collected 1–10 years before IBD onset, analyze blood glycosylation patterns by mass spectrometry, and run complementary lab studies in mouse models to test effects on the intestinal glycocalyx and inflammation.
The study aims to link PFAS mixtures with future IBD risk and to test whether altered glycosylation precedes Crohn’s disease or ulcerative colitis. If successful, the work could identify biomarkers of preclinical disease and suggest environmental mechanisms that raise IBD risk. This is a funded research project (R01) and does not report results yet.
The article is a Newswise press release describing the grant and the planned research; it summarizes the investigators, cohort source (PREDICTS), and laboratory approaches but does not present study data or findings.
This is a grant announcement describing planned research—no patient-facing findings or clinical recommendations are presented. The study will analyze archived samples and run lab models; any implications for patient care will depend on future results and independent validation.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This project seeks new biology-based treatments for IBD by finding bacterial enzymes that block PAR signaling, a pathway linked to inflammation, barrier loss, and pain — symptoms many people with Crohn’s disease or...
This project investigates how estrogen receptor signaling in intestinal epithelial cells drives sex-specific responses to injury and inflammation that may influence ulcerative colitis risk and progression.
This project studies a novel enzyme target (GCPII) that is reportedly upregulated in IBD and may change glutamate signaling and barrier function; understanding it could point to new treatment strategies for people whose...
